Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.51 |
| ▸ | GPR18 | Q14330 | 2/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 6/20 | 0.44 |
| ▸ | HTR7 | P34969 | 6/20 | 0.44 |
| ▸ | HTR6 | P50406 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | PAK4 | O96013 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812153 | 0.91 | CCNE2 (0.49) | EIF2AK2GPR18CCNE2CCNE1CDK2 | |
| SCHEMBL2808062 | 0.89 | CDK2 (0.40) | EIF2AK2GPR18CCNE2CCNE1CDK2 | |
| SCHEMBL2808392 | 0.87 | CCNE2 (0.49) | EIF2AK2GPR18CCNE2CCNE1CDK2 | |
| SCHEMBL2814487 | 0.85 | BCDIN3D (0.40) | CCNE2CCNE1CDK2MEN1KMT2A | |
| SCHEMBL2810910 | 0.83 | ADORA3 (0.44) | MEN1KMT2AMAPT | |
| SCHEMBL13145613 | 0.83 | BCDIN3D (0.35) | GPR18KMT2AMAPT | |
| SCHEMBL2809950 | 0.82 | BCDIN3D (0.38) | CCNE2CCNE1CDK2MEN1KMT2A | |
| SCHEMBL2812029 | 0.82 | PDE5A (0.40) | MEN1KMT2AMAPT | |
| SCHEMBL2816693 | 0.81 | CCNE2 (0.40) | EIF2AK2GPR18CCNE2CCNE1CDK2 | |
| SCHEMBL2812452 | 0.81 | TP53 (0.41) | DRD2MEN1KMT2AMAPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | EIF2AK2 1147/4885GPR18 3294/4885CCNE2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.